Screener
Halozyme Therapeutics HALO Long-Term Debt
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by Halozyme Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtNoncurrent.
The source filing: Halozyme Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001159036-26-000104
FAQ
- What is Halozyme Therapeutics's long-term debt?
- Halozyme Therapeutics (HALO) reported long-term debt of $1.94B in Q2 2026.
- How has Halozyme Therapeutics's long-term debt changed year-over-year?
- Halozyme Therapeutics's long-term debt increased by 28.4% year-over-year, from $1.51B to $1.94B.
- What does long-term debt mean?
- Bonds, term loans, notes payable, and other borrowings with maturities beyond one year — the primary long-term financing source.
Ask your AI about Halozyme Therapeutics's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI

Claude